Raymond James Financial Inc. bought a new stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 157,519 shares of the biopharmaceutical company's stock, valued at approximately $554,000. Raymond James Financial Inc. owned about 0.46% of Achieve Life Sciences as of its most recent filing with the SEC.
A number of other large investors also recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in Achieve Life Sciences by 6.9% in the third quarter. Geode Capital Management LLC now owns 749,109 shares of the biopharmaceutical company's stock valued at $3,552,000 after purchasing an additional 48,474 shares during the last quarter. State Street Corp grew its position in shares of Achieve Life Sciences by 6.8% during the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company's stock worth $2,045,000 after buying an additional 27,419 shares during the period. Barclays PLC increased its stake in shares of Achieve Life Sciences by 303.1% in the 3rd quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company's stock valued at $226,000 after acquiring an additional 35,832 shares during the last quarter. Verition Fund Management LLC bought a new stake in shares of Achieve Life Sciences in the 3rd quarter valued at about $113,000. Finally, SG Americas Securities LLC raised its position in shares of Achieve Life Sciences by 74.8% in the 4th quarter. SG Americas Securities LLC now owns 19,886 shares of the biopharmaceutical company's stock valued at $70,000 after acquiring an additional 8,512 shares during the period. Institutional investors and hedge funds own 33.52% of the company's stock.
Insider Buying and Selling at Achieve Life Sciences
In related news, CFO Mark K. Oki purchased 10,000 shares of Achieve Life Sciences stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,000 shares of the company's stock, valued at $28,900. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.00% of the company's stock.
Achieve Life Sciences Trading Up 4.3 %
Achieve Life Sciences stock traded up $0.09 during midday trading on Friday, hitting $2.18. 207,679 shares of the stock were exchanged, compared to its average volume of 180,807. Achieve Life Sciences, Inc. has a 52 week low of $1.84 and a 52 week high of $5.59. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $75.61 million, a PE ratio of -1.93 and a beta of 1.59. The company has a fifty day simple moving average of $2.85 and a two-hundred day simple moving average of $3.73.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.06). Equities research analysts anticipate that Achieve Life Sciences, Inc. will post -1.17 EPS for the current fiscal year.
About Achieve Life Sciences
(
Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Further Reading
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
